FilingSEC EDGAR6-K
Agomab Announces Positive Phase 1 Results for AGMB-447 and Prepares for Phase 2
· SEC accepted
StagePhase 1 completed, Phase 2 planned
Filing content
Agomab reported positive safety and target engagement data from its Phase 1 study of AGMB-447 in IPF patients and plans to initiate a Phase 2 study by year-end.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…